Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 3.56% is 24% below its 5-year average of 4.69%, around the middle of its 5-year range (-0.07%–7.27%).
13.50% below its 12-month average of 4.12%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 4.80%.
EBITDA MARGIN
3.56%
EBITDA MARGIN AVG TTM
4.12%
EBITDA MARGIN AVG 3Y
4.00%
EBITDA MARGIN AVG 5Y
4.69%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-13.50%
CURRENT VS 3Y AVG
-11.02%
CURRENT VS 5Y AVG
-24.12%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
BrightSpring Health Services, Inc. Common Stock
Market Cap
$12.17B
EBITDA Margin
3.56%
TTM Avg
4.12%
3Y Avg
4.00%
5Y Avg
4.69%
Market Cap
$12.00B
EBITDA Margin
23.27%
TTM Avg
22.46%
3Y Avg
26.66%
5Y Avg
22.37%
Market Cap
$12.52B
EBITDA Margin
5.99%
TTM Avg
7.75%
3Y Avg
3.55%
5Y Avg
8.89%
Market Cap
$12.89B
EBITDA Margin
16.91%
TTM Avg
18.03%
3Y Avg
18.32%
5Y Avg
17.35%
Market Cap
$12.95B
EBITDA Margin
-111.55%
TTM Avg
-188.02%
3Y Avg
-1871.48%
5Y Avg
-2339.83%
Market Cap
$11.36B
EBITDA Margin
28.74%
TTM Avg
23.07%
3Y Avg
27.33%
5Y Avg
30.04%
Market Cap
$13.19B
EBITDA Margin
6.13%
TTM Avg
13.31%
3Y Avg
19.35%
5Y Avg
24.86%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BrightSpring Health Services, Inc. Common Stock (BTSG) | $12.17B | 3.56% | 4.12% | 4.00% | 4.69% |
| Encompass Health Corporation (EHC)vs › | $12.00B | 23.27% | 22.46% | 26.66% | 22.37% |
| Penumbra, Inc. (PEN)vs › | $12.49B | 14.73% | 11.96% | 9.26% | 5.60% |
| Baxter International Inc. (BAX)vs › | $12.52B | 5.99% | 7.75% | 3.55% | 8.89% |
| DaVita Inc. (DVA)vs › | $11.47B | 19.98% | 20.97% | 19.78% | 20.10% |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 16.91% | 18.03% | 18.32% | 17.35% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.95B | -111.55% | -188.02% | -1871.48% | -2339.83% |
| Bio-Techne Corporation (TECH)vs › | $11.36B | 28.74% | 23.07% | 27.33% | 30.04% |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 6.13% | 13.31% | 19.35% | 24.86% |
| BioMarin Pharmaceutical Inc. (BMRN)vs › | $11.12B | 19.03% | 19.69% | 15.98% | 11.44% |
Gross Margin
12.4%
EBITDA Margin
3.6%
Operating Margin
3.3%
Net Margin
2.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 4.80% |
| 2026-03-31 | 4.89% |
| 2025-12-31 | 4.16% |
| 2025-09-30 | 3.86% |
| 2025-06-30 | 2.87% |
| 2025-03-31 | 3.23% |
| 2024-12-31 | 4.39% |
| 2024-09-30 | 3.70% |
| 2024-06-30 | 3.64% |
| 2024-03-31 | 1.47% |
| 2023-12-31 | 5.02% |
| 2023-09-30 | -0.07% |
| 2023-06-30 | 5.99% |
| 2023-03-31 | 5.02% |
| 2022-12-31 | 3.90% |
| 2022-09-30 | 4.40% |
| 2022-06-30 | 6.04% |
| 2022-03-31 | 6.04% |
| 2021-12-31 | 6.38% |
| 2021-09-30 | 6.76% |
| 2021-06-30 | 7.27% |
| 2021-03-31 | 6.87% |
| 2020-12-31 | 6.73% |
| 2020-09-30 | 6.78% |
| 2020-06-30 | 6.23% |
| 2020-03-31 | 6.23% |
| 2019-12-31 | 3.60% |
| 2019-09-30 | 3.75% |
| 2019-06-30 | 3.20% |
